Driven by technology and other factors, the growth of China's biopharmaceutical market scale is far faster than that of other market segments

[analysis of pharmaceutical network market] with the aggravation of aging and the promotion of pharmaceutical policies, the pharmaceutical market in China has maintained a rapid growth trend According to frost Sullivan report, from 2014 to 2018, the scale of China's pharmaceutical market increased from 1.1 trillion yuan to 1.5 trillion yuan with an annual compound growth rate of 8.1%, and will reach 3.2 trillion yuan by 2030 It is understood that the Chinese medicine market is mainly composed of three parts: chemical medicine, biological medicine and traditional Chinese medicine Among them, biopharmaceutics started late in the Chinese pharmaceutical market, but due to its good safety, effectiveness and compliance, the market developed rapidly According to the industry, at present, driven by technological progress, industrial restructuring and increased payment capacity, the growth rate of China's biopharmaceutical market is far faster than that of China's overall pharmaceutical market and other market segments In addition, the policy aspect gives our country biological medicine industry very good support and encouragement Under the influence of favorable policies such as the guiding opinions on promoting the healthy development of the pharmaceutical industry, the opinions on deepening the reform of the review and approval system and encouraging the innovation of pharmaceutical medical devices, and the technical guidelines for accepting overseas clinical trial materials of drugs, the speed of drug review and approval has been significantly accelerated in recent years, and the time from the test to the registration and approval of biological drugs has been greatly shortened, The pharmaceutical innovation ability has been improved and the industry has developed rapidly In order to improve the safety, effectiveness and quality controllability of drugs, China has also established a strict regulatory system covering all aspects of drug research, production, circulation and use, which is conducive to promoting the development of biomedical industry towards standardization and high quality At the same time, it also provides new development opportunities for the biomedical industry, especially the priority approval system is conducive to the emergence of drugs independently developed by biomedical industry enterprises According to incomplete statistics in the industry, in 2019, there will be 9 class 1 new drugs independently researched and developed in China, which will be approved or about to be launched, involving diabetes, cancer, Alzheimer's disease, infection and other fields Among them, the first new drug, pegylated losenapeptide, independently developed by Haosen in Jiangsu Province, is the first domestic long-acting GLP-1 agonist; benwemod, a psoriasis treatment drug independently developed by Wenfeng Tianji in Beijing; colistin, a new drug jointly developed by Chinese Academy of Medical Sciences and Shenyang Tonglian group; flumatenide mesylate, a new drug of Haosen , PD-1 carrelizumab independently developed by Hengrui pharmaceutical, etc In the face of broad development space and fierce market competition, domestic enterprises continue to increase R & D investment, which further promotes the rapid development of China's biopharmaceutical market Data shows that in recent years, China's drug R & D expenditure has been increasing year by year, and it is expected that the growth rate will be maintained at more than 20% in 2019-2023 Large pharmaceutical companies pay more attention to R & D Among them, from 2015 to 2018, the total R & D expenses of Hengrui Pharmaceutical Co., Ltd were RMB 890 million, RMB 1.18 billion, RMB 1.75 billion and RMB 2.67 billion respectively; the total R & D expenses of Fosun Pharmaceutical Co., Ltd were RMB 830 million, RMB 1.1 billion, RMB 1.53 billion and RMB 2.5 billion respectively; the total R & D expenses of Shanghai Pharmaceutical Co., Ltd were RMB 620 million, RMB 670 million, RMB 836 million and RMB 1.389 billion respectively